Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans

被引:29
作者
Werner, U
Werner, D
Mundkowski, R
Gillich, M
Brune, K
机构
[1] Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany
[2] Univ Rostock, Dept Expt & Clin Pharmacol & Toxicol, D-18055 Rostock, Germany
来源
JOURNAL OF CHROMATOGRAPHY B | 2001年 / 760卷 / 01期
关键词
rofecoxib;
D O I
10.1016/S0378-4347(01)00256-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An easy, rapid and selective method for the determination of rofecoxib in human plasma is presented. The analytical technique is based on reversed-phase high-performance liquid chromatography coupled to atmospheric pressure chemical ionisation mass spectrometry (Finnigan Mat LCQ ion trap). The retention time of rofecoxib was 1.2 min. The method has been validated over a linear range from 1 to 500 mug/1 using celecoxib as internal standard. After validation, the method was used to study the pharmacokinetic profile of rofecoxib in 12 healthy volunteers after administration of a single oral dose (12.5 mg). The presented method was sufficient to cover more than 95% of the area under the curve. The pharmacokinetic characteristics (mean +/- SD) were t(max): 2.4 +/- 1.0 h, c(max): 147 +/- 34 mug/1, AUC(x): 2038 +/- 581 mug h/1 and t(1/2): 11.3 +/- 2.1 h. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:83 / 90
页数:8
相关论文
共 8 条
[1]   Determination of Rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection [J].
Chavez-Eng, CM ;
Constanzer, ML ;
Matuszewski, BK .
JOURNAL OF CHROMATOGRAPHY B, 2000, 748 (01) :31-39
[2]   Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans [J].
Depré, M ;
Ehrich, E ;
Van Hecken, A ;
De Lepeleire, I ;
Dallob, A ;
Wong, P ;
Porras, A ;
Gertz, BJ ;
De Schepper, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (02) :167-174
[3]  
Heinzel G, 1993, TOPFIT 2 0 PHARMACOK
[4]  
Hinz B, 2000, Curr Opin Anaesthesiol, V13, P585, DOI 10.1097/00001503-200010000-00017
[5]  
*MSD, 1999, PROD INF
[6]   Rofecoxib [J].
Scott, LJ ;
Lamb, HM .
DRUGS, 1999, 58 (03) :499-505
[7]   ANALYTICAL METHODS VALIDATION - BIOAVAILABILITY, BIOEQUIVALENCE, AND PHARMACOKINETIC STUDIES [J].
SHAH, VP ;
MIDHA, KK ;
DIGHE, S ;
MCGILVERAY, IJ ;
SKELLY, JP ;
YACOBI, A ;
LAYLOFF, T ;
VISWANATHAN, CT ;
COOK, CE ;
MCDOWALL, RD ;
PITTMAN, KA ;
SPECTOR, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (03) :309-312
[8]   Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection [J].
Woolf, E ;
Fu, I ;
Matuszewski, B .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1999, 730 (02) :221-227